Stocks Health care STRO
NASDAQ · Health careSutro Biopharma, Inc. (STRO)
Sutro Biopharma, Inc. brought in $45.7M of revenue over the twelve months to June 30, 2026, down 56.3% from a year earlier. It posted a net loss of $180.6M. At June 30, 2026 it held $54.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Sutro Biopharma, Inc.
- Net worth
- Sutro Biopharma, Inc. has a market value (market cap) of $175.9M at the latest share price, and shareholders' equity of -$103.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $102.5M (+65.2% year on year), with a net loss of $191.1M. Over the 12 months to June 30, 2026: revenue $45.7M, net loss $180.6M.
- Cash flow
- In fiscal 2025 operations used $177.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sutro Biopharma, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Sutro Biopharma, Inc. does
Sutro Biopharma, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker STRO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $102.5M | -$191.1M | -$22.49 | n/a |
| 2024 | $62M | -$227.5M | -$29.40 | n/a |
| 2023 | $153.7M | -$106.8M | -$17.68 | n/a |
| 2022 | $67.8M | -$119.2M | -$23.34 | n/a |
| 2021 | $61.9M | -$105.5M | -$22.75 | n/a |
| 2020 | $42.7M | -$32.1M | -$9.83 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where STRO ranks in Health care
Latest SEC filings
What Sutro Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 85% to $9.8M versus the same quarter last year; diluted EPS -$2.33 versus -$1.35.
- August 12, 2026
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- June 8, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 17% to $14.5M versus the same quarter last year; diluted EPS -$2.94 versus -$9.08.
Insider trades
What the people running Sutro Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER | Exercised options | 3,750 | - |
| September 18, 2026 | Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER | Shares withheld for tax | 1,345 | $20.6K |
| June 2, 2026 | Chow Gregory K.CFO | Exercised options | 2,500 | - |
| March 4, 2026 | Chung JaneChief Executive Officer, Director | Exercised options | 788 | - |
| March 4, 2026 | Chung JaneChief Executive Officer, Director | Shares withheld for tax | 282 | $6K |
| March 4, 2026 | Pauling DavidChief Admin. Ofcr. & GC | Exercised options | 675 | - |
| March 4, 2026 | Pauling DavidChief Admin. Ofcr. & GC | Shares withheld for tax | 277 | $5.9K |
| March 2, 2026 | Chung JaneChief Executive Officer, Director | Exercised options | 7,750 | - |
Who owns STRO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Perceptive Advisors LLC13G, passive with 2 related filers | 7.9% | August 14, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 7.6% | February 18, 2026 |
| Affinity Asset Advisors, LLC13G, passive with 1 related filers | 6.5% | May 14, 2026 |
| Srinivas Akkaraju13G, passive with 4 related filers | 6.4% | May 15, 2026 |
| Kynam Capital Management, LP13G, passive with 2 related filers | 5.27% | May 15, 2026 |
| Coastlands Capital LP13G, passive with 4 related filers | 5.14% | November 9, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 100 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Perceptive Advisors LLC | 1,304,846 | +589,539 |
| Bvf Inc | 1,251,788 | 0 |
| Affinity Asset Advisors, LLC | 1,172,487 | +102,968 |
| BlackRock, Inc. | 1,122,655 | +889,971 |
| Samsara Biocapital, LLC | 1,062,872 | 0 |
| Kynam Capital Management, LP | 872,558 | 0 |
| Orbimed Advisors LLC | 743,944 | -57,200 |
| Balyasny Asset Management L.P. | 711,162 | +245,370 |
| Vanguard Capital Management LLC | 694,219 | -26,223 |
| Eventide Asset Management, LLC | 585,262 | -130,045 |
| Velan Capital Investment Management LP | 512,160 | 0 |
| Woodline Partners LP | 458,029 | +588 |
| ADAR1 Capital Management, LLC | 404,014 | -120,427 |
| Geode Capital Management, LLC | 389,692 | +218,306 |
| Millennium Management LLC | 365,972 | +155,594 |
| State Street Corp | 305,979 | +253,861 |
| Merck & Co., Inc. | 272,351 | 0 |
| Acuta Capital Partners, LLC | 270,251 | +826 |
| Ameriprise Financial Inc | 244,669 | new |
| Point72 Asset Management, L.P. | 237,827 | -454,284 |
Insiders
4 insiders reported holding 48,125 shares in total, about $510.6K at the last price.
| Holder | Shares |
|---|---|
| Chung JaneChief Executive Officer, Director | 21,285 |
| Gerber Hans-PeterCHIEF SCIENTIFIC OFFICER | 12,367 |
| Pauling DavidChief Admin. Ofcr. & GC | 9,748 |
| Chow Gregory K.CFO | 4,725 |
Questions about STRO
What does Sutro Biopharma, Inc. do?
Sutro Biopharma, Inc. is a company in the Health care sector, listed on NASDAQ as STRO. Its shares trade on NASDAQ under the ticker STRO.
What is Sutro Biopharma, Inc.'s net worth?
Sutro Biopharma, Inc. has a market value (market cap) of $175.9M at the latest share price, and shareholders' equity of -$103.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sutro Biopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $180.6M on revenue of $45.7M.
How much revenue does Sutro Biopharma, Inc. make?
Over the twelve months to June 30, 2026 Sutro Biopharma, Inc. reported revenue of $45.7M. That is 56.3% less than a year earlier.
When did Sutro Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from November 9, 2026.
When is Sutro Biopharma, Inc.'s next earnings report?
Sutro Biopharma, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare STRO with
Follow STRO
Get an email when Sutro Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sutro Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.